Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 9/20 | 0.41 |
| ▸ | GUCY1B1 | Q02153 | 9/20 | 0.41 |
| ▸ | HTR3A | P46098 | 5/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.33 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.33 |
| ▸ | CFD | P00746 | 3/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25977708 | 0.87 | GUCY1A1 (0.39) | GUCY1A1GUCY1B1HTR3ASPRGUCY1B2 | |
| Acetic Acid SCHEMBL15065428 | 0.87 | GUCY1A1 (0.43) | GUCY1A1GUCY1B1HTR3A | |
| SCHEMBL10071130 | 0.83 | GUCY1A1 (0.39) | GUCY1A1GUCY1B1GUCY1B2GUCY1A2 | |
| SCHEMBL19158836 | 0.81 | SPR (0.42) | GUCY1A1GUCY1B1HTR3ASPRGUCY1B2 | |
| SCHEMBL326955 | 0.81 | GUCY1A1 (0.39) | GUCY1A1GUCY1B1HTR3A | |
| SCHEMBL15633063 | 0.81 | GUCY1A1 (0.38) | GUCY1A1GUCY1B1HTR3AGUCY1B2GUCY1A2 | |
| SCHEMBL326986 | 0.79 | GUCY1A1 (0.38) | GUCY1A1GUCY1B1HTR3AGUCY1B2GUCY1A2 | |
| SCHEMBL326615 | 0.76 | GUCY1A1 (0.37) | GUCY1A1GUCY1B1GUCY1B2GUCY1A2 | |
| SCHEMBL25975554 | 0.71 | SPR (0.42) | GUCY1A1GUCY1B1HTR3ASPR | |
| SCHEMBL13732186 | 0.70 | GUCY1A1 (0.43) | GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257398-A1 | PYRIMIDINE-BASED TRICYCLIC COMPOUND AND USE THEREOF | CHIA TAL TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257398-A1 | PYRIMIDINE-BASED TRICYCLIC COMPOUND AND USE THEREOF | TYMP, TYMS, DPYD | GUCY1A1 2940/4885GUCY1B1 2239/4885HTR3A 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.